Your browser doesn't support javascript.
loading
Interactions of anti-Parkinson drug benserazide with Zn(II), Cu(II), Fe(II) ions.
Szyrwiel, Lukasz; Pap, József S; Malinka, Wieslaw; Szewczuk, Zbigniew; Kotynia, Aleksandra; Brasun, Justyna.
Afiliación
  • Szyrwiel L; Department of Chemistry of Drugs, Wroclaw Medical University, ul. Borowska 211, 50-552 Wroclaw, Poland; CNRS/UPPA, LCABIE, UMR5254, Hélioparc, 2, av. Pr. Angot, F-64053 Pau, France. lukasz.szyrwiel@am.wroc.pl
J Pharm Biomed Anal ; 76: 36-43, 2013 Mar 25.
Article en En | MEDLINE | ID: mdl-23291441
ABSTRACT
One of the treatments of Parkinson disease is based on increasing the brain dopamine level by L-DOPA (LD) applications. To prevent the peripheral degradation of levodopa, another drug, benserazide is applied. On the other hand, during this neurodegenerative disease changes in the homeostasis of metals are observed and the increasing brain zinc levels are postulated to have therapeutic effects. Here we present studies on interactions of Zn(II), Cu(II), Fe(II) ions with benserazide and with benserazide/levodopa in ternary system. By applying mass spectrometry and UV-vis methods we describe the interactions between selected metal ions and the drug additives in the investigated systems. The results show forming of equimolar complexes in the binary and ternary systems.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Zinc / Benserazida / Cobre / Hierro Idioma: En Revista: J Pharm Biomed Anal Año: 2013 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Zinc / Benserazida / Cobre / Hierro Idioma: En Revista: J Pharm Biomed Anal Año: 2013 Tipo del documento: Article País de afiliación: Francia